BioRem Statistics
Total Valuation
BioRem has a market cap or net worth of 31.57 million. The enterprise value is 27.70 million.
| Market Cap | 31.57M |
| Enterprise Value | 27.70M |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 16.12M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.61% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | n/a |
| Float | 15.79M |
Valuation Ratios
The trailing PE ratio is 20.84.
| PE Ratio | 20.84 |
| Forward PE | n/a |
| PS Ratio | 1.27 |
| PB Ratio | 3.61 |
| P/TBV Ratio | 3.61 |
| P/FCF Ratio | 19.76 |
| P/OCF Ratio | 17.11 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.34, with an EV/FCF ratio of 17.34.
| EV / Earnings | 18.29 |
| EV / Sales | 1.09 |
| EV / EBITDA | 10.34 |
| EV / EBIT | 12.04 |
| EV / FCF | 17.34 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.89 |
| Quick Ratio | 1.56 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 0.84 |
| Debt / FCF | 1.39 |
| Interest Coverage | 18.58 |
Financial Efficiency
Return on equity (ROE) is 19.05% and return on invested capital (ROIC) is 34.42%.
| Return on Equity (ROE) | 19.05% |
| Return on Assets (ROA) | 7.52% |
| Return on Invested Capital (ROIC) | 34.42% |
| Return on Capital Employed (ROCE) | 21.47% |
| Weighted Average Cost of Capital (WACC) | 7.82% |
| Revenue Per Employee | 733,325 |
| Profits Per Employee | 44,558 |
| Employee Count | 34 |
| Asset Turnover | 1.33 |
| Inventory Turnover | 10.47 |
Taxes
In the past 12 months, BioRem has paid 551,493 in taxes.
| Income Tax | 551,493 |
| Effective Tax Rate | 26.69% |
Stock Price Statistics
The stock price has increased by +13.64% in the last 52 weeks. The beta is 0.70, so BioRem's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +13.64% |
| 50-Day Moving Average | 1.68 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 62.47 |
| Average Volume (20 Days) | 6,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioRem had revenue of 24.93 million and earned 1.51 million in profits. Earnings per share was 0.07.
| Revenue | 24.93M |
| Gross Profit | 6.05M |
| Operating Income | 2.25M |
| Pretax Income | 2.07M |
| Net Income | 1.51M |
| EBITDA | 2.48M |
| EBIT | 2.25M |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 5.99 million in cash and 2.21 million in debt, with a net cash position of 3.78 million.
| Cash & Cash Equivalents | 5.99M |
| Total Debt | 2.21M |
| Net Cash | 3.78M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.76M |
| Book Value Per Share | 0.55 |
| Working Capital | 8.39M |
Cash Flow
In the last 12 months, operating cash flow was 1.85 million and capital expenditures -247,541, giving a free cash flow of 1.60 million.
| Operating Cash Flow | 1.85M |
| Capital Expenditures | -247,541 |
| Free Cash Flow | 1.60M |
| FCF Per Share | n/a |
Margins
Gross margin is 24.25%, with operating and profit margins of 9.03% and 6.08%.
| Gross Margin | 24.25% |
| Operating Margin | 9.03% |
| Pretax Margin | 8.29% |
| Profit Margin | 6.08% |
| EBITDA Margin | 9.96% |
| EBIT Margin | 9.03% |
| FCF Margin | 6.41% |
Dividends & Yields
BioRem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.61% |
| Shareholder Yield | 3.61% |
| Earnings Yield | 4.80% |
| FCF Yield | 5.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRem has an Altman Z-Score of 3.77 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.77 |
| Piotroski F-Score | 5 |